Veradermics (MANE) Cash & Equivalents (2024 - 2026)

Veradermics (MANE) has 3 years of Cash & Equivalents data on file, last reported at $168.4 million in Q1 2026.

• Quarterly Cash & Equivalents changed N/A year-over-year to $168.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $168.4 million (changed N/A YoY) and the FY2025 annual result came in at $21.8 million, down 59.0% from the prior year.
• Cash & Equivalents grew to $168.4 million in Q1 2026, from $21.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $168.4 million in Q1 2026 to a low of $21.8 million in Q4 2025.
• A 3-year average of $81.1 million and a median of $53.1 million in 2024 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 59.0% in 2025, down 59.0% in 2025.
• Tracing MANE's Cash & Equivalents over 3 years: stood at $53.1 million in 2024, then sank by 59.0% to $21.8 million in 2025, then surged by 673.74% to $168.4 million in 2026.
• The last three Cash & Equivalents figures came in at $168.4 million (Q1 2026), $21.8 million (Q4 2025), and $53.1 million (Q4 2024), per Business Quant data.